Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a r ...

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available o ...

The latest trading session saw Ginkgo Bioworks Holdings, Inc. (DNA) ending at $0.37, denoting a +0.3% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.5%. Elsewhere, the Dow saw an upswing of 0.5%, while the tech-heavy Nasdaq depreciated by 1.28%. The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its forthcoming earnings report. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $0.30, moving +0.6% from the previous trading session. This change outpaced the S&P 500's 2.32% loss on the day. Elsewhere, the Dow lost 1.25%, while the tech-heavy Nasdaq lost 3.64%. Prior to today's trading, shares of the company had lost 5.9% over the past month. This has lagged the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79% in that time. Market participants will be closely following the financial results of Gi ...

If you are a shareholder of Ginkgo Bioworks Holdings, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/ginkgobioworks-holdings-inc/ Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https ...

Given that analysts also expect Ginkgo's top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this point. Meanwhile, on April 10, Ginkgo and Novo Nordisk (NYSE:NVO) disclosed they had expanded their strategic partnership. Under the five-year deal, the firms will seek "to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medicatio ...

According to a press release, Ginkgo aims to "develop and optimize" a microbial strain for a secondary metabolite under Syngenta's pipeline. On a scientific basis, Syngenta's research team has identified the biological solution as a high-potential asset. Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. The agricultural technology (or agritech) market is sizable, having reached a valuation of $23.5 billion in 2022. Further, Zion Mark ...

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can ...

A recovery plan is underway, but it isn't a slam dunk. To say that Ginkgo Bioworks' (DNA -10.03%) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had walked out the door months ago. But with the biotech's ambitious vision for highly automated biopharma manufacturing still unrealized, there may yet be rewards waiting for those who hold on for a bit longer. Or shareholders could just experience even mor ...

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.30 per share and a revenue of $175. ...